Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Blankenstein

Showing results (111-120 of 138) with videos related to

Pageof 14
Sort By:
Plos One|April 6, 2012
Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in miceArmin Gerbitz, Madhusudhanan Sukumar, Florian Helm, et al.
Human Gene Therapy|October 1, 2009
Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinomaAlexander Buchner, Heike Pohla, Gerald Willimsky, et al.
The Journal of Experimental Medicine|October 5, 2016
Preventing tumor escape by targeting a post-proteasomal trimming independent epitopeAna Textor, Karin Schmidt, Peter-M Kloetzel, et al.
Cancer Immunology Research|January 18, 2017
Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient SurvivalNatalie J Miller, Candice D Church, Lichun Dong, et al.
Human Gene Therapy|March 28, 2026
In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>Reno Debets, Robert Hawkins, David Gilham, et al.
The Journal of Experimental Medicine|January 19, 2017
Correction: Preventing tumor escape by targeting a post-proteasomal trimming independent epitopeAna Textor, Karin Schmidt, Peter-M Kloetzel, et al.
Human Gene Therapy|June 18, 2026
In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>Reno Debets, Robert Hawkins, David Gilham, et al.
Science Advances|June 8, 2022
IFN-γ-dependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasisLaure Garnier, Robert Pick, Julien Montorfani, et al.
Nature Immunology|February 22, 2023
Publisher Correction: IFNγ binding to extracellular matrix prevents fatal systemic toxicityJosephine Kemna, Evelyne Gout, Leon Daniau, et al.
Journal for Immunotherapy of Cancer|June 3, 2025
Enhanced mutanome analysis towards the induction of neoepitope-reactive T-cell responses for personalized immunotherapy of pancreatic cancerMichael Volkmar, Dana Hoser, Claudia Lauenstein, et al.
Pageof 14

Showing results (111-120 of 138) with videos related to

Sort By:
Pageof 14
Plos One|April 6, 2012
Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in miceArmin Gerbitz, Madhusudhanan Sukumar, Florian Helm, et al.
Human Gene Therapy|October 1, 2009
Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinomaAlexander Buchner, Heike Pohla, Gerald Willimsky, et al.
The Journal of Experimental Medicine|October 5, 2016
Preventing tumor escape by targeting a post-proteasomal trimming independent epitopeAna Textor, Karin Schmidt, Peter-M Kloetzel, et al.
Cancer Immunology Research|January 18, 2017
Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient SurvivalNatalie J Miller, Candice D Church, Lichun Dong, et al.
Human Gene Therapy|March 28, 2026
In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>Reno Debets, Robert Hawkins, David Gilham, et al.
The Journal of Experimental Medicine|January 19, 2017
Correction: Preventing tumor escape by targeting a post-proteasomal trimming independent epitopeAna Textor, Karin Schmidt, Peter-M Kloetzel, et al.
Human Gene Therapy|June 18, 2026
In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>Reno Debets, Robert Hawkins, David Gilham, et al.
Science Advances|June 8, 2022
IFN-γ-dependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasisLaure Garnier, Robert Pick, Julien Montorfani, et al.
Nature Immunology|February 22, 2023
Publisher Correction: IFNγ binding to extracellular matrix prevents fatal systemic toxicityJosephine Kemna, Evelyne Gout, Leon Daniau, et al.
Journal for Immunotherapy of Cancer|June 3, 2025
Enhanced mutanome analysis towards the induction of neoepitope-reactive T-cell responses for personalized immunotherapy of pancreatic cancerMichael Volkmar, Dana Hoser, Claudia Lauenstein, et al.
Pageof 14